Tranexamic acid

Tranexamic acid. Excipient name: polyethylene glycol 400.

This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. For secondary hyperfibrinolytic state caused by disseminated intravascular coagulation, this product is generally not used before heparinization. This product is also suitable for: 1. Traumatic or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, and thyroid glands. 2. Used as an antagonist of tissue plasminogen activator (t→PA), streptokinase, and urokinase. 3. Fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism. 4. Excessive menstruation, hyphema hemorrhage, and severe epistaxis caused by pathologically increased local fibrinolysis in the uterine cavity. 5. Mild bleeding caused by rupture of a central aneurysm, such as subarachnoid hemorrhage and intracranial aneurysm bleeding.

Generally, adults should take 0.25-0.5g of intravenous drip at a time. If necessary, 1-2g can be taken per mouthful, divided into 1-2 times. The dosage can be appropriately increased or decreased according to age and symptoms, or as directed by the doctor. To prevent bleeding before and after surgery, the above dosage can be used as a reference.

This product has fewer adverse reactions than 6-aminocaproic acid. Occasionally, drug overdose may cause intracranial thrombosis and bleeding; there are also diarrhea, nausea and vomiting; less common are menstrual discomfort (caused by blood coagulation during menstruation)

Store in airtight, cool and dark place (avoid light and not exceed 20℃).

API

Changzhou Yinsheng Pharmaceutical Co., Ltd.

• Founded in:

  2003-04-21

• Address:

  Xutang Chemical Industry Zone, Xinbei District, Changzhou

• Tax NO.:

  91320411748725474U

• Registered Funds:

  20 million yuan

• Website:

  Log in to view

• Email:

  Log in to view